The following table summarizes the employee termination benefits related activity for the February 2025 Plan and other prior restructuring plans (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2025	$	2.7	$	10.4	$	13.1
Charged to expense - employee termination benefits	0.5		—		0.5
Adjustments to expense	0.2		0.1		0.3
Cash payments	(2.7)		(7.7)		(10.4)
Foreign currency adjustments	(0.1)		0.1		—
Balances as of September 30, 2026	$	0.6	$	2.9	$	3.5

Restructuring costs incurred under the July 2026 Plan during the three and nine months ended September 30, 2026, which also represent cumulative costs incurred since inception, were as follows (in millions):


	Life Science		Clinical Diagnostics		Total
Employee termination benefits	$	26.3	$	46.4	$	72.7
Facility exit and other costs (1)	2.2		2.7		4.9
	$	28.5	$	49.1	$	77.6

(1) Includes a non-cash reduction in carrying value of property, plant and equipment of approximately $2.2 million

The following table summarizes the employee termination benefits related activity of our July 2026 plan restructuring liabilities (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2025	$	—	$	—	$	—
Charged to expense - employee termination benefits	26.3		46.4		72.7

Cash payments	(4.1)		(4.5)		(8.6)
Foreign currency adjustments	(0.5)		(0.8)		(1.3)
Balances as of September 30, 2026	$	21.7	$	41.1	$	62.8


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2026		2025		2026		2025
Cost of goods sold	$	24.7	$	(0.6)	$	24.5	$	4.1
Selling, general and administrative expense	41.4		2.4		42.2		20.3
Research and development expense	11.1		0.7		9.4		13.7
Total restructuring expense	$	77.2	$	2.5	$	76.1	$	38.1